Just ahead of the formal close of its massive acquisition of Shire PLC - and amid news of the even larger planned $74bn merger of Bristol-Myers Squibb Co. and Celgene Corp. - Takeda Pharmaceutical Co. Ltd. has signaled its commitment to the immune approach in oncology, unveiling multiple research collaborations aimed at bolstering its early-stage pipeline in the area.
New Takeda R&D Collabs Aim To Boost IO Pipeline
In moves aimed at boosting its presence in the immuno-oncology field, Takeda unveils a series of new research collaborations it believes will lead to pipeline gains in this critical field over the next few years.
More from Anticancer
More from Therapy Areas
• By
Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.
• By
JAK inhibitor gains ninth indication in US after a strong performance in the first quarter.
• By
CSPC’s SYS6010, the first monospecific EGFR-targeting antibody-drug conjugate in the clinic for advanced NSCLC, has shown Phase I promise, but could face close competition with another China-originated bispecific.